Здоровье без побочных эффектов

14. IMS Health reports U.S. prescription sales grew 51. percent in 2009, to $3003. billion. IMS Health press release. 2010 April 1.

15. Kessler R.C., Demler O., Frank R.G., et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med. 2005; 352: 2515–23.

16. Spence D. The psychiatric oligarchs who medicalise normality. BMJ. 2012; 344: e3135.

17. Gross J. Checklist for camp: bug spray, sunscreen, pills. New York Times. 2006 July 16.

18. Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.

19. Schwarz A. Attention disorder or not, pills to help in school. New York Times. 2012 Oct 9.

20. GFK Denmark. [Focus group about treatment of ADHD in children and adolescents]. Letter. 2011 Nov 23.

21. Whitaker R. Anatomy of an Epidemic. New York: Broadway Paperbacks; 2010.

22. Morbidity and Mortality Weekly Report. Current depression among adults – United States, 2006 and 2008. JAMA. 2010; 304: 2233–5.

23. The Patient Health Questionnaire (PHQ-9). Available online at: Available online at: www.agencymeddirectors.wa.gov/Files/depressoverview.pdf (accessed 20 October 2012).

24. Healy D. Let them eat Prozac. New York: New York University Press; 2004.

25. Frances A. Antidepressant use has gone crazy: bad news from the CDC. Psychiatric Times. 2011 Oct 28.

26. Friedman R.A. Grief, depression, and the DSM-5. N Engl J Med. 2012; 366: 1855–7.

27. Nielsen M., Gøtzsche P. An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products. Int J Risk Saf Med. 2011; 23: 125–32.

28. Open letter to DSM-5. Online petition. Available online at: www.ipetitions.com/petition/dsm5/.

29. Spence D. Bad medicine: bipolar II disorder. BMJ. 2011; 342: d2767.

30. Martin A., Young C., Leckman J.F., et al. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med. 2004; 158: 773–80.

31. Shea S.E., Gordon K., Hawkins A., et al. Pathology in the Hundred Acre Wood: a neurodevelopmental perspective on A.A. Milne. CMAJ. 2000; 163: 1557–9.

32. The creation of the Prozac myth. The Guardian. 2008 Feb 27.

33. Spence D. Bad medicine: adult attention-deficit/hyperactivity disorder. BMJ. 2011; 343: d7244.

34. Aagaard L., Hansen E.H. The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsychiatr Dis Treat. 2011; 7: 729–44.

35. More fraud from drug giant GlaxoSmithKline companies – court documents show. Child Health Safety. 2010 Dec 1.

36. Rennie D. When evidence isn’t: trials, drug companies and the FDA. J Law Policy. 2007 July: 991–1012.

37. Nemeroff C.B., Mayberg H.S., Krahl S.E., et al. VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacol. 2006; 31: 1345–55.

38. Volpe M. Dr. Charles Nemeroff and Emory University’s culture of corruption. The Provocateur. 2009 July 10.

39. Nugent T. Profi le in courage: A beleaguered whistle-blower physician fights for patients and jobs – and wins. Opednews. 2012 Nov 1.

40. Keller M.B., McCullough J.P., Klein D.N., et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000; 342: 1462–70.

41. Angell M. Is academic medicine for sale? N Engl J Med. 2000; 342: 1516–8.

42. Larson J.C., Ensrud K.E., Reed S.D., et al. Effi cacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011; 305: 267–74.

43. Coupland C., Dhiman P., Morriss R., et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011; 343: d4551.

44. McHugh P.R., Slavney P.R. Mental illness – comprehensive evaluation or checklist? N Engl J Med. 2012; 366: 1853–5.

45. Kleinman A. Rebalancing academic psychiatry: why it needs to happen – and soon. Br J Psych. 2012; 201: 421–2.

46. Lacasse J.R., Leo J. Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med. 2005; 2: e392.

47. Goldacre B. Bad Pharma. London: Fourth Estate; 2012.

48. Castrén E. Is mood chemistry? Nat Rev Neurosci. 2005; 6: 241–6.